{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T12:27:36Z","timestamp":1764332856524,"version":"3.37.3"},"reference-count":18,"publisher":"Bentham Science Publishers Ltd.","issue":"3","funder":[{"name":"Centre of Excellence in Research, Value Innovation and Entrepreneurship (CERVIE), UCSI University","award":["FPS-013"],"award-info":[{"award-number":["FPS-013"]}]},{"DOI":"10.13039\/501100003093","name":"Ministry of Education Malaysia","doi-asserted-by":"publisher","award":["FRGS\/2\/2014\/SKK02\/UCSI\/02\/1"],"award-info":[{"award-number":["FRGS\/2\/2014\/SKK02\/UCSI\/02\/1"]}],"id":[{"id":"10.13039\/501100003093","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDDT"],"published-print":{"date-parts":[[2021,5]]},"abstract":"<jats:sec>\n<jats:title>Aims::<\/jats:title>\n<jats:p>To utilize in silico-based approach for investigating the ability of PEGylated rapamycin as a\ncompetitive inhibitor to Galectin-3 for curing various diseases or that may provide an attractive strategy for\ntreatment of a wide variety of tumors.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Background::<\/jats:title>\n<jats:p>Galectin-3 (Gal-3) signaling protein is a unique member of lectin family present at the cell surface, intracellularly\nin both the nucleus and cytoplasm and extracellularly in the general circulation. Circulating Gal-3 is present in\nboth normal and cancer cells. High levels of circulating Gal-3 have been proven to be associated with inflammation and\nfibrosis in several acute and chronic conditions, which include neurological degeneration, inflammatory and immune\nresponses, autoimmune diseases, diabetes, heart failure, atherosclerosis, response to infection, wound healing, liver,\nlung, and kidney disease. Gal-3 is known to regulate many biological activities including cell adhesion, angiogenesis,\ngrowth, apoptosis, migration, and metastasis. Rapamycin has been examined alone or in combination with other drugs\nfor treatment of various cancers in clinical studies. Although it has shown promising therapeutic effects, its clinical development\nwas interrupted by poor aqueous solubility and limited preferential distribution. To overcome these limitations,\nRA has been chemically modified to hydrophilic analogues, such as everolimus (EV). However, all these approaches\ncan only partially increase the solubility, but has little effect on the blood distribution and pharmacokinetics.\nTherefore, it is necessary to explore other RA conjugates to improve aqueous solubility and tissue distribution profile.\nRecently we reported that RP-MPEG inhibits the growth of various cancer cell lines by acting on mammalian target of\nRP (mTOR) receptor site and it can be used for gastric cancer.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objective::<\/jats:title>\n<jats:p>To construct various molecular weight RP-MPEG by replacing MPEG chain in 40-O-(2-\nhydroxyethyl) position of the EV and analyze their binding affinity to Gal-3.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods::<\/jats:title>\n<jats:p>The chemical structures of various molecular weight RP-MPEG were built using ChemSketch software.\nThe molecular docking study was performed to find the best probable structure of RP-MPEG for competitive inhibition\nof the CRD, based on the interaction score. For that purpose, the 3D structures of RP and EV were obtained\nfrom NCBI PubChem compound database, where the structural protein-co-crystallized ligand complex of Gal-3\n(TD2, as a native ligand) was retrieved from RCSB Protein Data Bank. All structures of the selected compounds,\nserved as molecules for molecular modeling, were optimized through MOE.2014 software before docking. Hydrogen\natoms and partial charges were added to the protein. Protein minimization was performed in gas solvation with\nthe side chains, keeping it rigid and the ligand flexible. The selected site was isolated and minimized, followed by\nprotonating the protein. The 3D ligands were minimized using MMFF94x with cutoffs of 10 to 12 \u00c5. The hydrogens\nand charges were fixed, and the RMS gradient was set to 0.001 kcal\/mol. The docking results were analyzed to\nidentify and assess the binding affinity of these compounds to CRD using drug discovery software.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results::<\/jats:title>\n<jats:p>Our results indicated that RP-MPEG with MW 1178.51 g\/mol has a logP value of 3.79 and has possessed\nthe strongest binding affinity toward CRD of Gal-3 with a docking score of -6.87. Compared with TD2,\nthere were additional close contacts for RP-MPEG (MW 1178.51 g\/mol), coming from three hydrogen bonds\nwith Asp148, Arg162, and Arg144 which suggest that this ligand is a strong competitive inhibitor among the\nother molecules for Gal-3.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion::<\/jats:title>\n<jats:p>RP-MPEG with the MW 1178.51 g\/mol could be a promising blocker for various biological action\nof Gal-3 includes profibrotic activity, modulation of immune responses and inflammatory responses to cancer\nthat contributes to neoplastic transformation, angiogenesis and metastasis.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Other::<\/jats:title>\n<jats:p>The 95% confidence intervals (CIs) of the binding affinity (according to their mean and standard errors)\nwere estimated with 2.5 and 97.5 percentile as the lower and upper bounds.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1570163817666200122162042","type":"journal-article","created":{"date-parts":[[2020,1,23]],"date-time":"2020-01-23T07:17:50Z","timestamp":1579763870000},"page":"451-456","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["In silico-based Approach to Investigate the Ability of PEGylated Rapamycin to Inhibit Galectin-3"],"prefix":"10.2174","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7515-6921","authenticated-orcid":true,"given":"Marwan Abdelmahmoud","family":"Abdelkarim Maki","sequence":"first","affiliation":[{"name":"Faculty of Pharmaceutical Sciences, UCSI University, No. 1, Jalan Menara Gading, Taman Connaught, Cheras 56000, Kuala Lumpur,Malaysia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1129-7084","authenticated-orcid":true,"given":"Palanirajan Vijayaraj","family":"Kumar","sequence":"additional","affiliation":[{"name":"Faculty of Pharmaceutical Sciences, UCSI University, No. 1, Jalan Menara Gading, Taman Connaught, Cheras 56000, Kuala Lumpur,Malaysia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manogaran","family":"Elumalai","sequence":"additional","affiliation":[{"name":"Faculty of Pharmaceutical Sciences, UCSI University, No. 1, Jalan Menara Gading, Taman Connaught, Cheras 56000, Kuala Lumpur,Malaysia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2638-8475","authenticated-orcid":true,"given":"Omer","family":"Bayazeid","sequence":"additional","affiliation":[{"name":"Department of Pharmacognosy, Faculty of Pharmacy, Hacettepe University, 06100 Ankara,Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1023\/B:GLYC.0000014084.01324.15","volume":"19","author":"Takenaka Y.","year":"2002","unstructured":"Takenaka Y.; Fukumori T.; Raz A.; Galectin-3 and metastasis. Glycoconj J 2002,19(7-9),543-549","journal-title":"Glycoconj J"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.canlet.2011.09.003","volume":"313","author":"Newlaczyl A.U.","year":"2011","unstructured":"Newlaczyl A.U.; Yu L-G.; Galectin-3--a jack-of-all-trades in cancer. Cancer Lett 2011,313(2),123-128","journal-title":"Cancer Lett"},{"key":"ref=3","doi-asserted-by":"publisher","DOI":"10.1017\/S1462399408000719","author":"Yang R-Y","year":"2008","unstructured":"Yang R-Y; Rabinovich GA; Liu F-T; Galectins: Structure, function and therapeutic potential. Expert Rev Mol Med 2008","journal-title":"Expert Rev Mol Med"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"177","DOI":"10.4251\/wjgo.v2.i4.177","volume":"2","author":"Yu L-G.","year":"2010","unstructured":"Yu L-G.; Circulating galectin-3 in the bloodstream: An emerging promoter of cancer metastasis. World J Gastrointest Oncol 2010,2(4),177-180","journal-title":"World J Gastrointest Oncol"},{"key":"ref=5","first-page":"1389","volume":"6","author":"Iurisci I.","year":"2000","unstructured":"Iurisci I.; Tinari N.; Natoli C.; Angelucci D.; Cianchetti E.; Iacobelli S.; Concentrations of galectin-3 in the sera of normal controls and cancer patients. Clin Cancer Res 2000,6(4),1389-1393","journal-title":"Clin Cancer Res"},{"key":"ref=6","volume":"4","author":"Lokesh B.V.S.","year":"2015","unstructured":"Lokesh B.V.S.; Kumar P.V.; Enhanced Cytotoxic Effect of Chemically Conjugated Polymeric Sirolimus against HT-29 Colon Cancer and A-549 Lung Cancer Cell Lines. J Pharm Drug Deliv Res 2015,4(2)","journal-title":"J Pharm Drug Deliv Res"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0024-3205(95)02233-3","volume":"58","author":"Dumont F.J.","year":"1996","unstructured":"Dumont F.J.; Su Q.; Mechanism of action of the immunosuppressant rapamycin. Life Sci 1996,58(5),373-395","journal-title":"Life Sci"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"613","DOI":"10.2174\/156720181105140922124759","volume":"11","author":"Kumar P.V.","year":"2014","unstructured":"Kumar P.V.; Lokesh B.V.; Designing and in-vitro characterization of micelle forming amphiphilic PEGylated rapamycin nanocarriers for the treatment of gastric cancer. Curr Drug Deliv 2014,11(5),613-620","journal-title":"Curr Drug Deliv"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"4957","DOI":"10.3892\/mmr.2016.5883","volume":"14","author":"Mengke N.S.","year":"2016","unstructured":"Mengke N.S.; Hu B.; Han Q.P.; Rapamycin inhibits lipopolysaccharide-induced neuroinflammation in vitro and in vivo. Mol Med Rep 2016,14(6),4957-4966","journal-title":"Mol Med Rep"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"5053","DOI":"10.21873\/anticanres.11074","volume":"36","author":"Michael J.V.","year":"2016","unstructured":"Michael J.V.; Wurtzel J.G.; Goldfinger L.E.; Inhibition of galectin-1 sensitizes HRAS-driven tumor growth to rapamycin treatment. Anticancer Res 2016,36(10),5053-5061","journal-title":"Anticancer Res"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1677\/JOE-09-0216","volume":"204","author":"Shimodahira M.","year":"2010","unstructured":"Shimodahira M.; Fujimoto S.; Mukai E.; Rapamycin impairs metabolism-secretion coupling in rat pancreatic islets by suppressing carbohydrate metabolism. J Endocrinol 2010,204(1),37-46","journal-title":"J Endocrinol"},{"key":"ref=12","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.116.004106","volume":"5","author":"Haller S.T.","year":"2016","unstructured":"Haller S.T.; Yan Y.; Drummond C.A.; Rapamycin attenuates cardiac fibrosis in experimental uremic cardiomyopathy by reducing marinobufagenin levels and inhibiting downstream pro\u2010fibrotic signaling. J Am Heart Assoc 2016,5(10)","journal-title":"J Am Heart Assoc"},{"key":"ref=13","first-page":"U201","author":"Poda G","year":"2005","unstructured":"Poda G; Tetko I.; Towards predictive ADME profiling of drug candidates: Lipophilicity and solubility. Abstracts of papers of the american chemical society 2005,U201-U202"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"13047","DOI":"10.1074\/jbc.273.21.13047","volume":"273","author":"Seetharaman J.","year":"1998","unstructured":"Seetharaman J.; Kanigsberg A.; Slaaby R.; Leffler H.; Barondes S.H.; Rini J.M.; X-ray crystal structure of the human galectin-3 carbohydrate recognition domain at 2.1-A resolution. J Biol Chem 1998,273(21),13047-13052","journal-title":"J Biol Chem"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1111\/j.1747-0285.2011.01283.x","volume":"79","author":"Collins P.M.","year":"2012","unstructured":"Collins P.M.; \u00d6berg C.T.; Leffler H.; Nilsson U.J.; Blanchard H.; Taloside inhibitors of galectin-1 and galectin-3. Chem Biol Drug Des 2012,79(3),339-346","journal-title":"Chem Biol Drug Des"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"14577","DOI":"10.1021\/ja105852y","volume":"132","author":"Diehl C.","year":"2010","unstructured":"Diehl C.; Engstr\u00f6m O.; Delaine T.; Protein flexibility and conformational entropy in ligand design targeting the carbohydrate recognition domain of galectin-3. J Am Chem Soc 2010,132(41),14577-14589","journal-title":"J Am Chem Soc"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1093\/bioinformatics\/btn334","volume":"24","author":"Ritchie D.W.","year":"2008","unstructured":"Ritchie D.W.; Kozakov D.; Vajda S.; Accelerating and focusing protein-protein docking correlations using multi-dimensional rotational FFT generating functions. Bioinformatics 2008,24(17),1865-1873","journal-title":"Bioinformatics"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/0006-291X(76)91195-5","volume":"68","author":"Nowak T.P.","year":"1976","unstructured":"Nowak T.P.; Haywood P.L.; Barondes S.H.; Developmentally regulated lectin in embryonic chick muscle and a myogenic cell line. Biochem Biophys Res Commun 1976,68(3),650-657","journal-title":"Biochem Biophys Res Commun"}],"container-title":["Current Drug Discovery Technologies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1570163817666200122162042","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/178527\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1570163817666200122162042","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,25]],"date-time":"2022-06-25T20:17:18Z","timestamp":1656188238000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/178527\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1570163817666200122162042","relation":{},"ISSN":["1570-1638"],"issn-type":[{"type":"print","value":"1570-1638"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-10-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-12-20","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-12-30","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}